Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 16/20 | 0.51 |
| ▸ | HCRTR2 | O43614 | 10/20 | 0.51 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.40 |
| ▸ | SCD | O00767 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1463183 | 1.00 | HCRTR1 (0.51) | HCRTR1HCRTR2PROKR1SCDPTGES | |
| SCHEMBL1463185 | 1.00 | HCRTR1 (0.51) | HCRTR1HCRTR2PROKR1SCDPTGES | |
| SCHEMBL1463256 | 0.89 | MGLL (0.46) | HCRTR1HCRTR2PROKR1SCDPTGES | |
| SCHEMBL1463255 | 0.89 | MGLL (0.46) | HCRTR1HCRTR2PROKR1SCDPTGES | |
| SCHEMBL1463252 | 0.89 | MGLL (0.46) | HCRTR1HCRTR2PROKR1SCDPTGES | |
| SCHEMBL1462956 | 0.89 | HCRTR1 (0.54) | HCRTR1HCRTR2 | |
| SCHEMBL1462950 | 0.89 | HCRTR1 (0.54) | HCRTR1HCRTR2 | |
| SCHEMBL1462954 | 0.89 | HCRTR1 (0.54) | HCRTR1HCRTR2 | |
| SCHEMBL1462266 | 0.87 | HCRTR1 (0.52) | HCRTR1HCRTR2 | |
| SCHEMBL1462269 | 0.87 | HCRTR1 (0.52) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303871-B1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-05-09 | — | — | EP | claimed |
| JP-2011529096-A | — | — | 2011-12-01 | — | — | JP | claimed |
| US-7923470-B2 | Benzooxazoles as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-04-12 | — | — | US | claimed |
| EP-2303871-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-04-06 | — | — | EP | claimed |
| WO-2010012620-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-04 | — | — | WO | claimed |
| US-20100029664-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-04 | — | — | US | claimed |
| US-8748430-B2 | Pyrrolidin-3yl-methylamine quinoxaline derivatives | Hoffmann-La Roche Inc (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748430-B2 | Pyrrolidin-3yl-methylamine quinoxaline derivatives | Hoffmann-La Roche Inc (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748430-B2 | Pyrrolidin-3yl-methylamine quinoxaline derivatives | Hoffmann-La Roche Inc (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120232084-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-13 | — | — | US | disclosed |
| US-20120232084-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-13 | — | — | US | disclosed |
| US-20120232084-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-13 | — | — | US | disclosed |
| US-8207220-B2 | Substituted benzothiazoles as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20110071154-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | KNUST HENNER | 2011-03-24 | — | — | US | disclosed |
| US-20110071154-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | KNUST HENNER | 2011-03-24 | — | — | US | disclosed |
| US-20110071154-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | KNUST HENNER | 2011-03-24 | — | — | US | disclosed |
| WO-2010012620-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-04 | — | — | WO | disclosed |
| US-20100029664-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029664-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029664-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071154-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | HCRTR1 2/4885HCRTR2 1/4885PROKR1 131/4885 |
| US-20100029664-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | HCRTR1 2/4885HCRTR2 1/4885PROKR1 131/4885 |
| US-20120232084-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | HCRTR1 2/4885HCRTR2 1/4885PROKR1 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.